Comparison Study Shows TheracosBio’s BRENZAVVY® Matches Dapagliflozin in Effectiveness for Chinese Patients with Type 2 Diabetes

TheracosBio has recently published a study titled “Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: a 24-week,…

Read MoreComparison Study Shows TheracosBio’s BRENZAVVY® Matches Dapagliflozin in Effectiveness for Chinese Patients with Type 2 Diabetes

Zatolmilast Receives Orphan Medicinal Product Designation from the European Commission: Promising First-in-Class Therapy for Fragile X Syndrome

Shionogi B.V., the European arm of Shionogi & Co., Ltd., has revealed that the European Commission has granted Orphan Medicinal Product designation to zatolmilast (BPN14770), an investigational treatment for Fragile…

Read MoreZatolmilast Receives Orphan Medicinal Product Designation from the European Commission: Promising First-in-Class Therapy for Fragile X Syndrome